Revolution Medicines price to book ratio RVMD

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: 15.4×
6-year median: 3.7×
Against its 6-year history: 92nd; percentile: 0 is its lowest day, 100 its highest
6-year range: 2.1× to 26.8×
Peer median: 6.0×

Revolution Medicines' price to book ratio is 15.4× as of Oct 23, 2026.

That is above its 6-year median of 3.7×, higher than on 92% of days in the last 6 years.

Over that time it ranged from 2.1× in May 2022 to 26.8× in Jul 2026.

The median for 10 biotech stocks of a similar size is 6.0×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	15.4×	9.6×	26.8×
2025	9.8×	2.6×	9.8×
2024	4.7×	2.7×	6.5×
2023	3.8×	2.2×	4.1×
2022	3.1×	2.1×	4.5×
2021	2.9×	2.7×	7.5×
2020	5.2×	3.7×	8.3×

Against its peers

Companies in Biotechnology nearest Revolution Medicines' size, closest first, today.

Company	Price to book ratio
RVMDRevolution Medicines	15.4×
ONCBeOne Medicines	8.3×
ALNYAlnylam Pharmaceuticals	22.1×
UTHRUnited Therapeutics	3.9×
INCYIncyte	3.7×
REGNRegeneron Pharmaceuticals	2.6×
EXELExelixis	8.7×
NBIXNeurocrine Biosciences	3.9×
HALOHalozyme Therapeutics	99.3×
VRTXVertex Pharmaceuticals	6.6×
TECHBIO-TECHNE	5.4×
Peer median	6.0×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Revolution Medicines

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.